SOLV
Solventum Corporation
$86.39
+1.58% 2026-10-20
Health CareS&P 500
SOLVSPY
1W
+0.1%
1M
-2.8%
3M
+9.9%
6M
+25.3%
YTD
+9.0%
1Y
+18.6%
Live chart
Loading live chart…
Grades vs sector
Momentum62nd pct in sectorB-
Momentum
62nd pct in sector
12-1 return: +27.7%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth18th pct in sectorD
Growth
18th pct in sector
Revenue growth (YoY): +2.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value60th pct in sectorB-
Value
60th pct in sector
Forward E/P: 8.4% · EBITDA/EV: 5.8%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability82nd pct in sectorA-
Profitability
82nd pct in sector
Profit margin: +17.3% · Return on equity: +34.0%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15rank 160 of 499 · 12-1 momentum % 24.7
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsSolventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
PR Newswire · Oct 19
Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
PR Newswire · Oct 15
Solv Wellness Names Dr. Christine Vaccaro Its First Chief Medical Officer
PR Newswire · Oct 14
Is SOLV Energy (MWH) A Bargain On Growth Despite Its Share Price Slide?
Simply Wall St. · Oct 08
Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?
Zacks · Oct 08
Key stats
Market cap$14.7B
P/E (trailing)10.6
P/E (forward)11.9
52-week range62.38 – 94.16
Revenue growth (YoY, latest qtr)+2.2%
Dividend yield0.00%
Analyst consensusBuy (13)
Mean price target$94.69 (+10%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +1 (DCF counts double).
▲Forward P/E vs sector11.9x vs median 17.6x
•Piotroski F-score6/9
•Altman Z2.2 (grey)
•Net debt / EBITDA1.6x
•Analyst target+10% (13 analysts)
Discounted cash flow
Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.70 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 4th pct
10.6×cheaper
Forward P/E
cheaper
sector median 17.6× · 24th pct
11.9×cheaper
EV / EBITDA
cheaper
sector median 15.8× · 7th pct
7.3×cheaper
Price / sales
cheaper
sector median 3.1× · 29th pct
1.8×cheaper
Price / book
cheaper
sector median 3.5× · 46th pct
3.1×cheaper
FCF yield
pricier
sector median 4.1% · 10th pct
-0.8%pricier
Forward EPS $7.25 vs trailing $8.17 (-11% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
54.7%
Operating margin
25.0%
FCF margin
-1.4%
Net margin
17.3%
Return on equity
29.9%
Return on invested capital
19.6%
Net debt / EBITDA
1.6×
Current ratio
1.0×
Interest cover
–
Cash conversion (OCF/NI)
0.1×
Piotroski F-score 6/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✗ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 2.2 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$95
+10%
Analysts
13
Buy
Range
$71–$113
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $8.3B | $1.6B | $-10.0M |
| 2024 | $8.3B | $479.0M | $805.0M |
| 2023 | $8.2B | $1.3B | $1.6B |
| 2022 | $8.1B | $1.3B | $1.4B |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +0.8%.
Earnings
Next report: 2026-11-05 · during market · EPS est 1.35
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | 1.91 | 2.55 | +33.8% |
| 2026-05-05 | 1.35 | 1.48 | +9.3% |
| 2026-02-26 | 1.50 | 1.57 | +5.0% |
| 2025-11-06 | 1.43 | 1.50 | +4.7% |
| 2025-08-07 | 1.45 | 1.69 | +16.2% |
| 2025-05-08 | 1.22 | 1.34 | +9.7% |
| 2025-02-27 | 1.31 | 1.41 | +7.8% |
| 2024-11-07 | 1.39 | 1.64 | +17.7% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $2.2B | +2.2% |
| 2026-03-31 | $2.0B | – |
| 2025-12-31 | $2.0B | – |
| 2025-09-30 | $2.1B | – |
| 2025-06-30 | $2.2B | – |
Analyst actions
BTIG
PT $95
2026-09-14 · reit
Buy → BuyPT $95
UBS
PT $101
2026-08-06 · main
Buy → BuyPT $101
Piper Sandler
PT $105
2026-08-06 · main
Overweight → OverweightPT $105
Wedbush
PT $101
2026-08-06 · main
Outperform → OutperformPT $101
Keybanc
PT $102
2026-08-06 · main
Overweight → OverweightPT $102
Stifel
PT $100
2026-08-06 · main
Buy → BuyPT $100
Insider trades
None
–
None · None
SELL–
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:03:10 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.